Kenny Lim
Apr 16, 2009

Allergan expands partnership with McCann Healthcare for new product launch

ASIA-PACIFIC - Leading global specialty pharmaceutical firm Allergan has appointed McCann Healthcare Worldwide Singapore to oversee the launch of its new drug, Latisse, across Asia-Pacific.

Allergan expands partnership with McCann Healthcare for new product launch
Latisse is the first drug to promote eyelash growth. The product is expected to roll out in the third quarter of this year in key Asian markets including Singapore.

In addition to Latisse, the McCann Worldgroup agency handles the advertising for other Allergan products including Botox and Juvederm. 

Gloria Ma, regional marketing manager Asia Pacific for Allergan, said: “Latisse fulfills a significant and previously unmet need in the medical aesthetic marketplace. We estimate global peak sales of Latisse could exceed $500 million per year.”

Rohit Sahgal, managing director, McCann Healthcare Worldwide Singapore, added: “This is a dynamic time for us and the Singapore healthcare communications industry, where more regional-oriented clients are looking to reinforce their brand positioning in the market. McCann Healthcare Worldwide Singapore has been partnering Allergan's regional facial aesthetics team for over two years and now with Latisse, we're entering a new and exciting category that will benefit millions of consumers everywhere.”
Source:
Campaign Asia

Related Articles

Just Published

6 hours ago

Agency Report Card 2024: Mindshare

Mindshare faced significant setbacks in APAC in 2024, losing nearly a billion dollars in client business and falling out of Campaign's top 20 rankings, highlighting the need for strategic renewal.

8 hours ago

2025 Cannes Contenders: Dentsu APAC leaders place ...

From the grippingly serious to the hilariously eccentric, three Dentsu creative and product leaders across APAC give their nods to award-worthy work that may win a Cannes Lions next week.

9 hours ago

'Media isn’t a commodity. Treating it like one is a ...

Ruben Schreurs tells Campaign why litigation, platform volatility, and outdated media models are distorting decision-making—and why advertisers need to focus less on adjacency panic, and more on strategic clarity.

9 hours ago

WPP never seized control of its destiny under Mark ...

Departing CEO had some notable successes, but the company has struggled.